Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities
Dose-dependent biological and anti-leukemia activity observed
IMGN779 combines a high-affinity, humanized anti-CD33 antibody with one of ImmunoGen's novel indolino-benzodiazepine payloads, called IGNs, which alkylate DNA without crosslinking, resulting in potent anti-leukemia activity with relative sparing of normal hematopoietic progenitor cells.
Safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, as well as initial anti-leukemia activity for IMGN779 through dose level seven were presented at EHA. Key findings included:
The Phase 1 trial is designed to establish the maximum tolerated dose and determine the recommended Phase 2 dose for IMGN779 administered as monotherapy. The trial is also intended to evaluate safety and tolerability and characterize PK, PD, and preliminary anti-leukemia activity in relapsed or refractory AML. Dose escalation continues.
"We have designed our DNA-alkylating IGNs to be ultra-potent while
providing the tolerability necessary for ongoing retreatment," said
Preclinical data for IMGN779 were also presented at EHA showing the agent is highly active in multiple AML xenograft models and is well-tolerated in preclinical repeat dosing regimens. Findings from the preclinical evaluation provided the foundation for the clinical evaluation of IMGN779 in AML.
Title: Initial results from a first-in-human study of IMGN779,
a CD33-targeting antibody-drug conjugate (ADC) with novel DNA alkylating
activity, in patients with relapsed or refractory AML
Title: Designing the next generation CD33-targeting ADC:
IMGN779, selected for potency, novel mechanism and preclinical
tolerability, with high activity in disseminated AML models and
Additional information - including the full abstracts - can be found at www.ehaweb.org.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®,
in three other clinical-stage ImmunoGen product candidates, and in
programs in development by partners Amgen, Bayer, Biotest, CytomX,
About Acute Myeloid Leukemia (AML)
AML is a cancer of the bone marrow cells that produce white blood cells. It causes the marrow to increasingly generate abnormal, immature white blood cells (blasts) that do not mature into effective infection-fighting cells. The blasts quickly fill the bone marrow, impacting the production of normal platelets and red blood cells. The resulting deficiencies in normal blood cells leave the patient vulnerable to infections, bleeding problems and anemia.
It is estimated that, in the
IMGN779 is the first antibody drug conjugate (ADC) to utilize one of ImmunoGen's new family of indolino-benzodiazepine cancer-killing agents known as IGNs. IMGN779 is comprised of a CD33-targeting antibody with a potent DNA-alkylating agent, the IGN DGN462, attached. The antibody serves to target the ADC to the CD33-positive AML cells which DGN462 can then kill. IMGN779 is wholly owned by ImmunoGen.
Indolino-benzodiazepine cancer-killing agents, or IGNs, are a new class of cancer-killing agent developed by ImmunoGen for use in ADCs. These ultra-potent, DNA-alkylating IGNs are expected to extend the types of cancers able to be effectively treated with ADC therapies beyond those addressable with ImmunoGen's well-established tubulin-acting agents. Such cancers can include ones insensitive to tubulin-acting agents and/or with reduced antigen expression.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN779, including risks related to preclinical and clinical
studies, their timings and results. A review of these risks can be found
in ImmunoGen's Annual Report on Form 10-K for the six-month transition
News Provided by Acquire Media